Air pollution and asthma: how can a public health concern inform care of individual patients?

Annals of Allergy, Asthma & Immunology

October 2014 Volume 113, Issue 4, Pages 343-346 CME Review

Overall Purpose:
Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planning Committee Members:

Chris Carlsten, MD, MPH, FRCPC (Author)

Anne K. Ellis, MD, MSc, FRCPC (Associate Editor)

Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)

Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Describe the established connection between exposure to air pollution and exacerbation of existing asthma
  • Develop approaches to identifying air pollution sources, beyond environmental tobacco smoke, that may be contributing to the exacerbation of a patient’s asthma
  • Discuss exposure-reduction measures that can be incorporated into asthma action plans, in cases where air pollution may be involved in an exacerbation, and counsel patients to reduce exposure to air pollution in order to maintain optimal asthma control
Additional information
Disclosure: 

M.H. Grayson has received research grants from Children’s Research Institute/Medical College of Wisconsin, Merck, National Institutes of Health (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, and National Institutes of Health (NIH). N.E. Alexis, C. Carlsten, A.K. Ellis, M.L. North have no relevant financial relationships to disclose. Reviewers and Education/Editorial staff have no relevant financial relationships to disclose. No unapproved/investigative use of a product/device is discussed.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC
Course opens: 
10/01/2014
Course expires: 
09/30/2016
Cost:
$0.00

Michelle L. North, PhD; Neil E. Alexis, PhD; Anne K. Ellis, MD, MSc; and Chris Carlsten, MD, MPH

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC

Accreditation Period

Course opens: 
10/01/2014
Course expires: 
09/30/2016

Price

Cost:
$0.00
Please login or create an account to take this course.